RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies  by Antoniou, Antonis C. et al.
1186 The American Journal of Human Genetics Volume 81 December 2007 www.ajhg.org
ARTICLE
RAD51 135GrC Modifies Breast Cancer Risk among BRCA2
Mutation Carriers: Results from a Combined Analysis
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RAD51 is an important component of double-stranded DNA–repair mechanisms that interacts with both BRCA1 and
BRCA2. A single-nucleotide polymorphism (SNP) in the 5′ untranslated region (UTR) of RAD51, 135GrC, has been
suggested as a possible modifier of breast cancer risk in BRCA1 and BRCA2 mutation carriers. We pooled genotype data
for 8,512 female mutation carriers from 19 studies for the RAD51 135GrC SNP. We found evidence of an increased breast
cancer risk in CC homozygotes (hazard ratio [HR] 1.92 [95% confidence interval {CI} 1.25–2.94) but not in heterozygotes
(HR 0.95 [95% CI 0.83–1.07]; , by heterogeneity test with 2 degrees of freedom [df]). When BRCA1 and BRCA2Pp .002
mutation carriers were analyzed separately, the increased risk was statistically significant only among BRCA2 mutation
carriers, in whom we observed HRs of 1.17 (95% CI 0.91–1.51) among heterozygotes and 3.18 (95% CI 1.39–7.27) among
rare homozygotes ( , by heterogeneity test with 2 df). In addition, we determined that the 135GrC variantPp .0007
affects RAD51 splicing within the 5′ UTR. Thus, 135GrC may modify the risk of breast cancer in BRCA2 mutation carriers
by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/
2 mutation carriers.
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Germline mutations in BRCA1 (MIM 113705) and BRCA2
(MIM 600185) confer high risks of breast and ovarian can-
cer. In a meta-analysis of mutation-positive families iden-
tified through population-based studies of breast and ovar-
ian cancer cases, the cumulative risks of breast cancer by
age 70 years were estimated to be 65% and 45% for BRCA1
and BRCA2 mutation carriers, respectively.1 However,
these and other population-based estimates of penetrance
have, in general, been lower than estimates based on fam-
ilies with multiple affected individuals.2–4 Moreover, the
breast cancer risk has been found to vary by the age at
diagnosis and the type of cancer in the index patient.1,5
Such observations are consistent with the hypothesis that
breast cancer risk in mutation carriers is modified by other
genetic or environmental factors that cluster in families.
RAD51 is the homolog of bacterial RecA, which is re-
quired for recombinational repair of double-strand DNA
breaks.6,7 Both BRCA1 and BRCA2 interact with RAD51,8,9
and the Rad51-knockout mouse phenotype resembles the
Brca1- and Brca2-knockout phenotypes.10 To examine the
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effect of RAD51 SNPs on cancer risk in BRCA1 and BRCA2
mutation carriers, Wang et al.11 searched for common se-
quence variants by resequencing the RAD51 gene. No
SNPs in the coding region were identified, but two SNPs
(135GrC [rs1801320] and 172GrT [rs1801321]) were dis-
covered in the 5′ UTR of RAD51. The latter SNP was found
to have no effect on cancer risk, but carriers of the 135C
allele were reported to have an increased risk of breast
cancer among the subset of BRCA2 carriers ( ; oddsnp 216
ratio [OR] 3.2 [95% CI 1.4–40]).11 Two additional studies
of the 135GrC SNP also found an association with cancer
risk in BRCA2 carriers. A study of Israeli Ashkenazi Jewish
carriers from 141 BRCA1 families and 64 BRCA2 families
found a significant association of the C allele with cancer
risk (breast or ovarian) in BRCA2 carriers (hazard ratio [HR]
of 4.0 [95% CI 1.3–9.2]), largely because of its effect on
breast cancer risk.12 Kadouri et al.13 also found an increased
risk of breast cancer (HR 2.09 [95% CI 1.04–4.18]) for
BRCA2 carriers and reported that the median age at onset
of breast cancer in BRCA2 carriers with the RAD51 C allele
was 7 years younger than that in RAD51 wild-type carriers.
In contrast, Jakubowska et al.14 evaluated this RAD51
SNP in a small study of 83 discordant pairs (affected with
breast cancer and unaffected) of female carriers of the
BRCA1 founder mutation 5382insC and observed a sig-
nificantly reduced risk of breast cancer among RAD51
135C allele carriers (OR 0.23 [95% CI 0.07–0.62]). In a
recent report by the same group,15 the effect was only
marginally significant among the 5382insC carriers (Pp
) and became more significant when carriers of the.046
two other BRCA1 Polish founder mutations (4153delA and
300TrG) were included in the analysis (OR 0.58 [95% CI
0.38–0.91]; ).Pp .018
Studies of genetic modifiers of BRCA1/2 have been ham-
pered by small sample size, such that the power to detect
even moderate effects on cancer risk has been limited. To
address this problem, we established CIMBA to conduct
collaborative analyses of genetic polymorphisms, involv-
ing many thousands of samples, as modifiers of cancer
risk in BRCA1 and BRCA2 mutation carriers.16 In this re-
port, we evaluate the association of the RAD51 135GrC
polymorphism (rs1801320) with breast cancer risk in
BRCA1 and BRCA2 female mutation carriers.
Material and Methods
Study Population
Eligible study subjects were women aged 18 years who carry a
pathogenic mutation in BRCA1 or BRCA2. Information on study
subjects was submitted from 19 participating studies from 13
countries. These women participated in clinical and research
studies at the host institutions under institutional review board–
approved protocols. Data collected included year of birth, mu-
tation description, family membership, ethnicity, country of
residence, age at last follow-up, ages at diagnosis of breast and
ovarian cancer, and information on bilateral prophylactic mas-
tectomy. Mutations were included in the analysis if they were
pathogenic according to generally recognized criteria (from the
Breast Cancer Information Core)—that is, (i) mutations gener-
ating a premature termination codon as a result of nonsense sub-
stitution, frameshift due to small deletion or insertion, aberrant
splicing, or large genomic rearrangement (excluding truncating
variants in exon 27 of BRCA2); (ii) mutations resulting in loss of
expression due to deletion of promoter and transcription start
site; (iii) large in-frame deletions spanning one or more exons
caused by aberrant splicing or large genomic rearrangement; and
(iv) missense mutations classified as pathogenic by use of the
algorithms of Goldgar et al.17 and Chenevix-Trench et al.18
The functional consequences of pathogenic BRCA1/2 muta-
tions may depend on their type.19–21 To examine whether the
effect of the RAD51 135GrC on breast cancer risk is different for
carriers of different types of BRCA1/2 mutations, we grouped the
mutations into two categories. Class 1 corresponds to loss-of-
function mutations expected to result in reduced transcript or
protein level because of mRNA nonsense-mediated decay (NMD)
and/or degradation or instability of truncated proteins,20–22 trans-
lation reinitiation but no production of stable protein,23 or the
absence of expression because of deletion of transcription regu-
latory regions. Class 2 consists of mutations likely to generate
potentially stable mutant protein that might have dominant neg-
ative action, partially preserved normal function, or loss of func-
tion. Class 2 mutations are missense substitutions and truncating
mutations with premature stop codon occurring in the last exon.
Genotyping
Most centers genotyped the 135GrC SNP in the 5′ UTR of RAD51
by the 5′ nuclease assay (TaqMan) on an ABI 7900HT Sequence
Detection System (Applied Biosystems). PCR primers were for-
ward primer 5′-GCTGGGAACTGCAACTCATCT-3′ and reverse
primer 5′-GCAGCGCTCCTCTCTCCAGC-3′. Probes were VIC-5′-
CAACGCCCGTGGCTTACGCT-3′ and FAM-5′-CCCCAACGCCC-
CTGGCTTAC-3′. The annealing temperature was 60C. The
Interdisciplinary Health Research International Team on Breast
Cancer Susceptibility (INHERIT BRCAs) and Iceland Landspitali-
University Hospital (ILUH) samples and most of the samples from
the Ontario Cancer Genetics Network (OCGN) were genotyped
by direct sequencing. INHERIT BRCAs and OCGN used forward
primer 5′-GTTTGGCGGGAATTCTGAAAGCCG-3′ and reverse
primer 5′-GTTCTAAAGACTGAGGTCCACTTG-3′. ILUH used for-
ward primer 5′-TGGGAACTGCAACTCATCTGG-3′ and reverse
primer 5′-GCGCTCCTCTCTCCAGCAG-3′. GCHBOC used the
iCycler technology (Bio-Rad Laboratories) with forward primer 5′-
GGGCAAGCGAGTAGAGAAGTG-3′ and reverse primer 5′-CGCG-
CTCCGACTTCAC-3′. Probes were VIC-5′-CAACGCCCCTGGCTT-
3′ and FAM-5′-ACGCCCGTGGCTT-3′. The International Hereditary
Cancer Centre (IHCC), Helsinki Breast Cancer Study (HEBCS),
Deutsche Krebsforschungszentrum (DKFZ), and National Israeli
Cancer Center Control (NICCC) used RFLP-PCR analysis, and Me-
morial Sloan-Kettering Cancer Center (MSKCC) used pyrosequ-
encing (details available on request). All centers included at least
2% of samples in duplicate, no template controls on every plate,
and a random mixture of samples of affected and unaffected mu-
tation carriers on each plate. The minimum accepted call rate was
95%. Call rates for each study were in the range 96%–100% (mean
98.5%). There was one discordant result (0.1%) among the 1,008
duplicates genotyped. For each study, the genotype frequencies
among unrelated carriers were consistent with the expected fre-
quencies under the assumption of Hardy-Weinberg equilibrium.
All reported CC homozygotes were confirmed by sequencing
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with use of forward primer 5′-GAGGGCAGTCTGTAAAACTC-3′
and reverse primer 5′-AACTGCCGCTGAGCACTGGA-3′. One pu-
tative homozygote was shown to be a GC heterozygote by se-
quencing; for another, there was no DNA available for sequenc-
ing, so it was excluded from the analysis.
A total of 8,606 mutation carriers with an observed RAD51
135GrC genotype were eligible for inclusion in the study. In
some instances, more than one study had enrolled carriers from
the same family. We therefore investigated for possible overlap
between studies by comparing the year of birth, mutation, and
the reported ages, to identify potential duplicate individuals.
When a potential duplicate was identified, we contacted the rel-
evant centers for further information about these individuals,
without revealing their identity. When potential overlap was
identified, centers were contacted to determine precisely the ex-
tent of true overlap in subjects and families appearing more than
once in the data set. To avoid having families extending over
several centers, we excluded the smallest version of the family.
In total, 94 carriers with a submitted genotype were excluded: 85
appeared twice in the data set, and 9 were excluded because they
were part of the family being studied at another center. The
RAD51 135GrC genotypes between the two submissions of the
85 carriers who appeared twice were identical (one was a CC
homozygote). A total of 8,512 unique BRCA1 and BRCA2 muta-
tion carriers remained for analysis (table 1).
Statistical Analysis
Individuals were classified according to their age at diagnosis of
breast cancer or their age at last follow-up. For this purpose, in-
dividuals were censored at the age at the first of the following
events: breast cancer diagnosis ( ), ovarian cancer di-np 4,443
agnosis ( ), bilateral prophylactic mastectomy ( ),np 798 np 176
or last observation ( ). For the purpose of our analysis,np 3,095
only carriers censored at breast cancer diagnosis were assumed to
be affected. To investigate whether our results were sensitive to
the inclusion of prevalent cancer cases, we also performed anal-
yses after excluding patients with breast or ovarian cancer diag-
nosed 15 years before their age at last follow-up. The 5-year cutoff
was selected to maintain a sample size that would still have rea-
sonable power to investigate the effects under consideration,
while excluding long-term survivors. Moreover, prognostic data
suggest that 5-year survival after breast cancer is ∼95%, so that,
within this time frame, survival bias would be minimal.24 The
same cutoff has been used in studies investigating environmental
modifiers of risk.25 For this analysis, we excluded subjects for
whom an age at interview was not provided. The IHCC study was
also excluded because only a censoring age was provided. This
left a total of 5,198 mutation carriers for the sensitivity analysis.
To examine whether our results are modified by consideration
of information on bilateral prophylactic oophorectomy (BPO),
we also performed analyses whereby carriers were censored at age
at BPO.26
The analysis of associations in BRCA1 and BRCA2 mutation
carriers is complicated by the fact that mutation carriers are not
randomly sampled with respect to their disease phenotype. Many
carriers are sampled through genetic clinics, and it is likely that
affected individuals are oversampled. In such cases, standard
methods of analysis, like Cox regression, do not give valid esti-
mates of the HRs.27 To correct for this potential bias, we analyzed
the data within a retrospective likelihood framework, by mod-
eling the likelihood of the observed RAD51 135GrC genotypes
and disease phenotypes conditional on the disease phenotypes28
(appendix A). In this model, the breast cancer incidence was as-
sumed to depend on the underlying RAD51 135GrC genotype
through a Cox proportional hazards model: ,l (t)p l (t) exp (b )i 0 i
where is the HR for genotype i and is the breast cancerexp (b ) l (t)i 0
incidence rate in the baseline category. We estimated the log-HRs
for genotypes GC and CC, using the GG homozygotes as the
baseline category. The baseline age-specific incidence rates were
chosen such that the overall breast cancer incidence rates, av-
eraged over all genotypic categories, agreed with external esti-
mates of BRCA1 and BRCA2 incidence rates. This process is de-
scribed in detail elsewhere.29 For this purpose, we used the
calendar-specific, cohort-specific (for cohorts based on birth year:
before 1920, 1920–1929, 1930–1939, 1940–1949, and 1950 and
after), and age-specific incidence rates derived using combined
data from the meta-analysis of the families of BRCA1/2 carriers
identified through population-based studies of breast and ovarian
cancer1 and data from three population-based studies of breast
cancer31–35 (A.C.A., unpublished data). These analyses were per-
formed using the pedigree analysis software MENDEL.30 We also
fitted models in which the log-relative hazards were allowed to
vary with age. Significance tests for the null hypothesis that the
log-HRs are equal to 0 were also performed using a score test
statistic based on the retrospective likelihood described above36
(also see appendix A). Between-study heterogeneity was exam-
ined by comparing the log-likelihood of models with study-spe-
cific log-HRs (logL1) against the log-likelihood of models in which
the same log-HR was assumed to apply to all studies (logL2). These
likelihood-ratio tests are approximate because of the small num-
bers of carriers in each study and the fact that some parameter
estimates converge to boundaries.
All analyses used mutation-, calendar-, and cohort-specific
breast cancer incidence rates and were stratified by study, country
of residence, and reported ethnicity. Analyses were performed for
BRCA1 and BRCA2 mutation carriers combined and separately.
Fourteen compound BRCA1 and BRCA2 mutation carriers were
included in all analyses. In all instances, a robust variance ap-
proach was used to allow for the dependence between related
carriers.37,38
RNA Extraction and RT-PCR
Total RNA was extracted from lymphoblastoid cell lines (in IN-
HERIT BRCAs and GEMO studies) with the RNeasy mini kit (QIA-
GEN) according to the manufacturer’s instruction, with a diges-
tion step by use of DNase I (QIAGEN). A total of 5 mg of RNA was
reverse transcribed with SuperScript II Rnase H-Reverse Transcrip-
tase (Invitrogen Life Technologies) by use of random primers (Pro-
mega). To explore the alternative splicing within the 5′ UTR of
RAD51, RT-PCR was performed in the presence of 1.5% dimethyl
sulfoxide (DMSO) by use of a forward primer located in the 5′
UTR (5′-AGACCGAGCCCTAAGGAGAG-3′) and a reverse primer
located at the exon 2–exon 3 junction (5′-CCACACTGCTCTAAC-
CGTGA-3′) (fig. 1). This RT-PCR was also performed in human
mammary epithelial cells (CC-2551 [Lonza]) and human breast
cancer cell lines MCF-7 (HTB-22 [ATCC]), MDA-MB-157 (HTB-24
[ATCC]), ZR-75-1 (CRL-1500 [ATCC]), and T47D (HTB-133
[ATCC]). To test whether the RAD51 5′ UTR isoform 2 was asso-
ciated with specific alternative splicing of coding exons, we per-
formed RT-PCR by using a forward primer specific to isoform 2
(5′-GAAGTGGAGCTAATGGCAATG-3′) and a reverse primer in
exon 7 (5′-CTGGTGGTCTGTGTTGAACG-3′). The amplified frag-
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Figure 1. RAD51 135GrC variant and alternative splicing within the 5′ UTR. A, Schematic representation and sequence of 5′ RAD51
exons. Exons are represented by hatched boxes (in 5′ UTR) and unblackened boxes (in coding region). Major splicing patterns are shown
by blue connecting lines above (for isoform 1) and below (for isoform 2) the gene scheme. ATG is the translation initiation codon.
The nucleotide sequence of the full-length 5′ UTR is in blue, the 5′ UTR sequence alternatively spliced as part of intron 1 is in italics,
and the canonical motif of the alternative 5′ splice site within the 5′ UTR is underlined. B, Results of the RT-PCR performed with the
primers shown in panel A in lymphoblastoid cell lines from carriers of three genotypes of the RAD51 135GrC variant. A predominant
RAD51 transcript with the longest 5′ UTR (isoform 1, with full-length 5′ UTR of length 257 nt [GenBank accession number NM_002875])
and a less abundant transcript, with the shortest 5′ UTR (isoform 2, with truncated 5′ UTR of length 153 nt [GenBank accession number
AK131299]), as well as several minor RAD51 transcript isoforms with intermediate 5′ UTR lengths characterized by sequencing, were
detected.
ments were sequenced using BDT V1.1 (Applied Biosystems) on
the ABI PRISM 3100 (Applied Biosystems). These experiments and
the quantitative real-time PCR measurements were performed in
the Cancer Genomics Laboratory, Centre Hospitalier Universi-
taire (CHU) de Quebec & Laval University, and in the Unite´ Mixte
de Ge´ne´tique Constitutionnelle des Cancers Fre´quents, Hospices
Civils de Lyon–Centre Le´on Be´rard, Lyon.
Quantitative Real-Time PCR Experiments
Experiment 1.—First-strand cDNA synthesis was performed using
1–5 mg of total RNA with Superscript III Rnase H-Reverse Tran-
scriptase (Invitrogen Life Technologies) and oligo-dT18. The re-
sulting products were purified with Qiaquick PCR purification kits
(QIAGEN). cDNA corresponding to 40–300 ng of total RNA was
used to perform fluorescent-based real-time PCR quantification
by use of LightCycler FastStart DNA MasterPlus SYBR Green I
(Roche) on the LightCycler Realtime PCR apparatus (Roche) as
described by the manufacturer. The amplification of RAD51 iso-
form 1 required the addition of 4% DMSO in the reaction mix
for PCR. To ensure that a specific fluorescence signal was read,
PCRs were brought for 3 s to a temperature a few degrees below
the melting temperature of DNA fragments. The fluorescence sig-
nal was then registered at this temperature at the end of each
cycle (for isoform 1, 84C; for isoform 2, 78C). A melting curve
was performed at the end of each run to assess nonspecific signal.
The primer pairs used for the specific amplification of RAD51
isoforms were as follows: for RAD51 isoform 1, forward primer
5′-AAGCGAGTAGAGAAGTGGAGCGTA-3′ and reverse primer 5′-
ACTGCTCTAACCGTGAAATGGG-3′; for RAD51 isoform 2, for-
ward primer 5′-AGAGAAGTGGAGCTAATGGCAATG-3′ and re-
verse primer 5′-ACTGCTCTAACCGTGAAATGGG-3′. The specific-
ity of isoform 1 primers was also verified by performing PCR with
the purified isoform 2 amplicon as a template, and no amplified
product was detected. The housekeeping gene glucose-6-phos-
phate dehydrogenase (G6PD [MIM 305900]) (forward primer 5′-
GATGTCCCCTGTCCCACCAACTCTG-3′; reverse primer 5′-GCA-
GGGCATTGAGGTTGGGAG-3′) was used for normalization.
Standard curves were established using serial dilutions of known
cDNA amounts for each RAD51 isoform and G6PD, and the ex-
pression was quantified as described elsewhere.39 All experiments
were done in duplicate.
Experiment 2.—A total of 2 mg of total RNA was reverse tran-
scribed using the First-Strand cDNA Synthesis Kit and pd(N)6
random primers (Amersham Biosciences). Quantification of RAD51
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Table 2. Patient Characteristics
Characteristic All Patients
BRCA1 Mutation Carriersa BRCA2 Mutation Carriersa
Unaffected
With Breast
Cancer Unaffected
With Breast
Cancer
No. of carriers 8,512 2,902 2,876 1,174 1,574
Length of follow-up (person-years) 363,476 122,953 118,711 52,575 69,825
Mean  SD age at censure (years) 42.9 11.2 42.6 12.5 41.4 9.3 45.1 13.1 44.5 10.1
Year of birth:
Before 1920 91 (1.1) 19 (.7) 29 (1.0) 17 (1.5) 26 (1.7)
1920–1929 334 (3.9) 74 (2.6) 115 (4.0) 43 (3.7) 102 (6.5)
1930–1939 829 (9.7) 214 (7.4) 291 (10.1) 105 (8.9) 221 (14.0)
1940–1949 1,704 (20.0) 422 (14.5) 701 (24.4) 193 (16.4) 389 (24.7)
1950–1959 2,590 (30.4) 807 (27.8) 985 (34.3) 299 (25.5) 504 (32.0)
1960 or later 2,964 (34.8) 1,366 (47.1) 755 (26.3) 517 (44.0) 332 (21.1)
Ethnicity:
White 6,935 (81.5) 2,344 (80.8) 2,351 (81.8) 916 (78.0) 1,334 (84.8)
Ashkenazi Jewish 1,329 (15.6) 473 (16.3) 425 (14.8) 229 (19.5) 206 (13.1)
African American 54 (.6) 17 (.6) 21 (.7) 9 (.8) 7 (.4)
Asian 57 (.7) 16 (.6) 26 (.9) 2 (.2) 13 (.8)
Hispanic 79 (.9) 29 (1.0) 28 (1.0) 12 (1.0) 10 (.6)
Other 58 (.7) 23 (.8) 25 (.9) 6 (.5) 4 (.3)
Parity:
Nulliparous 693 (8.1) 285 (9.8) 190 (6.6) 123 (10.5) 95 (6.0)
1 child 652 (7.7) 190 (6.6) 249 (8.7) 89 (7.6) 124 (7.9)
2 children 1,564 (18.4) 486 (16.8) 544 (18.9) 222 (18.9) 314 (20.0)
3 children 885 (10.4) 257 (8.9) 303 (10.5) 141 (12.0) 185 (11.8)
4 children 517 (6.1) 168 (5.8) 154 (5.4) 86 (7.3) 110 (7.0)
Data missing 4,201 (49.4) 1,516 (52.2) 1,436 (49.9) 513 (43.7) 746 (47.4)
Oophorectomy:
None 4,148 (48.7) 1,275 (43.9) 1,457 (50.6) 621 (52.9) 803 (51.0)
BPO 452 (5.3) 243 (8.4) 62 (2.2) 105 (8.9) 42 (2.7)
Data missing 3,912 (46.0) 1,384 (47.7) 1,357 (47.2) 448 (38.2) 729 (46.3)
NOTE.—Data are no. (%) of carriers, unless otherwise indicated.
a Includes 14 compound BRCA1 and BRCA2 mutation carriers.
isoform 1 and isoform 2 expression by real-time PCR was per-
formed using LightCycler FastStart DNA MasterPLUS SYBR Green I
(Roche) on the LightCycler 2.0 instrument (Roche) as described
by the manufacturer. Primer pairs used for specific amplification
of RAD51 isoforms were as follows: for RAD51 isoform 1, forward
primer 5′-GGCCTGCTGGAGAGAGGA-3′ and reverse primer 5′-
CCACACTGCTCTAACCGTGA-3′; for RAD51 isoform 2, forward
primer 5′-GAAGTGGAGCTAATGGCAATG-3′ and reverse primer
5′-CCACACTGCTCTAACCGTGA-3′. A melting curve was per-
formed at the end of each run to assess nonspecific signal. The
levels of the reference housekeeping genes glyceraldehyde-3-
phosphatase dehydrogenase (GAPDH [MIM 138400]) (forward
primer 5′-AGCCACATCGCTCAGACAC-3′ and reverse primer 5′-
GCCCAATACGACCAAATCC-3′) and b-actin (ACTB [MIM
102630]) (forward primer 5′-ATTGGCAATGAGCGGTTC-3′ and re-
verse primer 5′-GGATGCCACAGGACTCCAT-3′) were quantified
using TaqMan probes UPL#60 and UPL#11, respectively, and
LightCycler Taqman Master (Roche) as described by the manu-
facturer. All experiments were done in duplicate and were nor-
malized to the geometric mean of the level of these reference
genes. Relative standard curves determining the PCR efficiencies
of the RAD51 isoforms, GAPDH, and ACTB were established using
cDNA serial dilutions. Efficiency-corrected and calibrator-nor-
malized calculations were performed using the LightCycler Rel-
ative Quantification Software (Roche). The nonparametric Krus-
kal-Wallis test was used to test for differences in the distribution
of expression levels between genotypes implemented in STATA
(version 8.2 for Unix [Statacorp]).
Results
A total of 8,512 BRCA1 and BRCA2 mutation carriers were
used in the analysis (tables 1 and 2). The overall RAD51
genotype frequencies (GC 13.3%; CC 0.7%) were similar
to those reported in population-based studies in the
United Kingdom and Australia,40,41 but there was some
variation in the frequencies between the CIMBA centers.
Carriers of the RAD51 135C allele were least common in
the Icelandic (ILUH) study and were most frequent among
Polish BRCA1 mutation carriers. The RAD51 genotype fre-
quencies were similar across the larger studies of GEMO,
Modifiers and Genetics in Cancer (MAGIC), GCHBOC,
EMBRACE, and kConFab.
The genotype frequencies by mutation and disease
status are shown in table 3, along with the estimated HRs.
There was evidence of association between the RAD51
135GrC genotype and breast cancer risk among BRCA1
and BRCA2 mutation carriers combined ( , by 2-Pp .002
df test). The estimated breast cancer HR was 0.95 (95% CI
0.83–1.07; ) in GC individuals and 1.92 (95% CIPp .292
1.25–2.94; ) in CC individuals. The estimatedPp .0008
HR for the CC homozygotes was higher among BRCA2
mutation carriers (HR 3.18 [95% CI 1.39–7.27]; Pp
) than among BRCA1 mutation carriers (HR 1.59.0004
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Table 3. RAD51 135GrC Genotype Distribution and
Estimated HRs in the Total Sample of BRCA1 and BRCA2
Mutation Carriers
Gene and
Genotype
or Test
No. (%) of Carriers
HR (95% CI) PaUnaffected
With Breast
Cancer
BRCA1/2:
GG 3,485 (85.6) 3,838 (86.4) 1.00 …
GC 565 (13.9) 567 (12.7) .95 (.83–1.07) .292
CC 19 (.5) 38 (.9) 1.92 (1.25–2.94) .0008
2-df Test … … … .002
Trend test … … … .801
BRCA1:
GG 2,456 (84.6) 2,475 (86.0) 1.00 …
GC 429 (14.8) 376 (13.1) .86 (.77–1.02) .095
CC 17 (.6) 25 (.9) 1.59 (.96–2.63) .067
2-df Test … … … .046
Trend test … … … .386
BRCA2:
GG 1,036 (88.2) 1,370 (87.0) 1.00 …
GC 136 (11.6) 191 (12.1) 1.17 (.91–1.51) .123
CC 2 (.2) 13 (.8) 3.18 (1.39–7.27) .0004
2-df Test … … … .0007
Trend test … … … .007
NOTE.—Compound BRCA1 and BRCA2 carriers were included in all
analyses.
a P value by the score test.
Table 4. RAD51 135GrC Genotype Distribution and
Estimated HRs by BRCA1 and BRCA2 Mutation Class
Mutation
Class
and Genotype
or Test
No. (%) of Carriers
HR (95% CI) PaUnaffected
With Breast
Cancer
BRCA1 class 1:
GG 1,639 (85.8) 1,562 (87.5) 1.00 …
GC 262 (13.7) 208 (11.6) .83 (.68–1.00) .058
CC 9 (.5) 16 (.9) 1.97 (1.05–3.70) .041
2-df Test … … … .021
Trend test … … … .284
BRCA1 class 2:
GG 753 (81.9) 825 (83.9) 1.00 …
GC 158 (17.2) 150 (15.3) .93 (.74–1.17) .567
CC 8 (.9) 8 (.8) 1.11 (.42–2.93) .780
2-df Test … … … .817
Trend test … … … .525
BRCA2 class 1:
GG 995 (87.8) 1,289 (87.0) 1.00 …
GC 136 (12.0) 179 (12.1) 1.14 (.88–1.48) .123
CC 2 (.2) 13 (.9) 3.24 (1.41–7.45) .0004
2-df Test … … … .0007
Trend test … … … .007
NOTE.—See main text for definition of mutation classes.
a P value by the score test.
[95% CI 0.96–2.63]), although the difference in HR was
not statistically significant. There were no statistically sig-
nificant differences between the estimated HRs for pa-
tients aged !40 years and those aged 40 years, for either
gene (results not shown). Likelihood-ratio tests suggest
some evidence of heterogeneity in the HR estimates
among centers for BRCA2 ( , ) but not for2x p 41.6 dfp 24
BRCA1 ( , ).2x p 32.7 dfp 32
To investigate whether our results were sensitive to the
inclusion of patients with cancer diagnosed a long time
before their recruitment into the various studies (i.e.,
“prevalent” cancer cases) who may introduce a survival
bias, we repeated our analysis after excluding patients with
breast or ovarian cancer diagnosed 15 years before their
last follow-up. The estimated HRs for CC individuals were
very similar to those obtained with the complete data set
(BRCA1/2 combined HR 2.36 [95% CI 1.31–4.26]; BRCA1
HR 1.98 [95% CI 0.88–4.46]; BRCA2 HR 3.37 [95% CI 1.33–
8.55]).
It is well established that BPO significantly reduces the
risk of breast cancer among BRCA1 and BRCA2 mutation
carriers.26,42 We therefore examined whether our results are
modified by considering the information on BPO, by cen-
soring carriers at BPO in two ways: mutation carriers with
missing information on BPO either were included in the
analysis under the assumption that they had not under-
gone BPO or were excluded from the analysis. When all
carriers were used in the analysis, the results were very
similar to those of the primary analysis (data not shown).
When subjects with missing information on BPO were
excluded, the HR among BRCA2 mutation carriers with
the GC genotype was estimated to be 1.35 (95% CI 0.97–
1.89) and, among BRCA2 carriers with the CC genotype,
was estimated to be 5.67 (95% CI 1.64–19.63). Thus, the
estimated HRs were comparable to those in the overall
analysis, although the effect in the combined sample of
BRCA1 and BRCA2 mutation carriers was no longer sta-
tistically significant.
Although there are limited experimental data on the
functional consequence of BRCA1 and BRCA2 mutations,
current evidence suggests that most of the premature stop-
codon mutations result in loss of function caused by re-
duced transcript and protein levels due to NMD and/or
instability of the truncated proteins (class 1 mutations).20–
23 On the other hand, missense or in-frame deletion/in-
sertion mutations, as well as truncating mutations that
are not subject to NMD, might generate stable mutant
protein that has consequences other than loss of function
(class 2 mutations). It is possible that the BRCA1/2 mu-
tations in these two categories may interact in different
ways with the potential cancer risk modifier effect of
RAD51 135GrC. Of the BRCA1 mutation carriers, 64%
carried class 1 mutations, 33% carried class 2 mutations,
and 3% carried mutations of unpredictable consequence
at transcript or protein level. The majority (95%) of the
BRCA2 mutation carriers carried class 1 mutations. There
was some indication that the RAD51 135GrC genotype
association was greater in carriers of class 1 BRCA1 mu-
tations, with an estimated HR among CC homozygotes of
1.97 (95% CI 1.05–3.70; ), and had no effect inPp .041
carriers of class 2 mutations (HR 1.11 [95% CI 0.42–2.93])
(table 4). However, the difference in the HRs by mutation
type was not statisically significant. The corresponding HR
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estimates among the GC heterozygotes did not differ sig-
nificantly from unity (0.83 [95% CI 0.68–1.00] and 0.93
[95% CI 1.05–3.70] for carriers of class 1 and class 2 BRCA1
mutations, respectively).
To evaluate whether the observed association between
the RAD51 135GrC genotype and breast cancer risk was
an indirect effect due to another (untested) variant in the
RAD51 region, we used the HapMap data for CEPH indi-
viduals from Utah data to identify SNPs in strong linkage
disequilibrium with 135GrC (International HapMap Pro-
ject). Fifty SNPs had an with 135GrC, in a region2r 1 0.50
of 285 kb. Of these, 44 were perfectly correlated with
135GrC ( ) and would not be distinguishable by2r p 1.0
genetic epidemiological studies in European populations.
Only 2 of the 50 SNPs, however, were located within
RAD51 ( and 0.51). SNP rs2304579 ( ) is in2 2r p 1.0 r p 1.0
the RAD51 intron 2 (IVS2110ArG), and SNP rs4144242
( ) is in intron 5 (IVS5-4016GrA). By use of soft-2r p 0.51
ware tools that assess splice sites and splice-enhancer mo-
tifs, these deep intronic SNPs were not predicted to be of
functional significance (SpliceSiteFinder, Splice Site Pre-
diction, and ESE Finder). Three of the other proxy SNPs
for RAD51 135GrC are located within the neighboring
cancer susceptibility candidate 5 gene (CASC5 [MIM
609173]). SNP rs10518696 is in an intron, and SNPs
rs8034726 and rs16970854 are in the promoter region.
CASC5 (also known as “AF15Q14” and “D40”) is a com-
ponent of the hMis12 kinetochore complex essential for
chromosome segregation43 and is fused to the MLL gene
as a result of translocations in some cases of acute lym-
phoblastic and myeloblastic leukemias.44–46 However,
there is no known interaction between CASC5 and BRCA1
or BRCA2, so we consider RAD51 to be the more plausible
modifier of risk.
The molecular mechanism by which the RAD51 135GrC
SNP results in increased breast cancer risk in BRCA2 mu-
tation carriers is unclear. Alternative splicing of the human
RAD51 gene, involving coding and noncoding exons, has
been reported in genomic databases (including GenBank).
Some mRNAs had 5′ UTRs shorter than the 5′ UTR of the
full-length RAD51 transcript (GenBank accession number
NM_002875), with 135GrC located 1 nt next to the ca-
nonical motif of the alternative 5′ splice site within the 5′
UTR (fig. 1A).
To investigate whether 135GrC is involved in the reg-
ulation of the pattern of the 5′ UTR alternatively spliced
RAD51 transcripts, we examined their relative abundance
in lymphoblastoid cell lines established from 5 CC ho-
mozygotes, 20 GC heterozygotes, and 20 GG homozygotes
by performing RT-PCR, encompassing the 5′ UTR, exon 1,
and exon 2, including the beginning of the coding region
(fig. 1A and 1B). Several RAD51 transcripts with varying
length for the 5′ UTR were detected. The two predominant
RAD51 transcripts had the longest and the shortest 5′
UTRs: isoform 1 (full-length 5′ UTR of 257 nt [GenBank
accession number NM_002875]) and isoform 2 (truncated
5′ UTR of 153 nt [GenBank accession number AK131299]),
generated by an alternative splicing within the 5′ UTR,
which removes the 104-nt 5′ UTR sequence recognized as
part of intron 1. These RT-PCR experiments suggested that
the level of the isoform 2 transcript varied between cell
lines with different 135GrC genotypes and was found to
be particularly low in CC homozygotes (fig. 1B). To in-
vestigate this observation further, we used quantitative
real-time PCR to compare the expression of the RAD51
isoforms 1 and 2 across three 135GrC genotypes. The
quantitative real-time PCR quantification was performed
in two laboratories with overlapping sets of samples, by
use of different housekeeping genes for normalizing the
RAD51 expression data. The results between the two ex-
periments were very similar and are shown in detail in
figure 2. There was no statistically significant difference
in the expression levels for isoform 1 among the three
genotypes (experiment 1, ; experiment 2,Pp .92 Pp
), but there were significant differences among the ge-.44
notypes in the expression of isoform 2 (experiment 1,
; experiment 2, ). Pairwise genotypePp .008 Pp .001
comparisons of the mean expression levels of isoform 2
revealed 3–7-fold differences between GG and CC ho-
mozygotes (experiment 1, ; experiment 2,Pp .007 Pp
) and 2–4-fold differences between GC heterozygotes.002
and CC homozygotes (experiment 1, ; experi-Pp .012
ment 2, ). There were no statistically significantPp .002
differences between the expression levels of isoform 2 be-
tween GG homozygotes and GC heterozygotes (experi-
ment 1, ; experiment 2, ).Pp .137 Pp .087
To test whether the RAD51 5′ UTR isoform 2 is associated
with specific alternative splicing of coding exons and may,
therefore, give rise to a variant RAD51 protein, we per-
formed RT-PCR, using the forward primer specific to iso-
form 2 and the reverse primer in exon 7 (see the “Material
and Methods” section), generating an amplicon covering
the RAD51 exons reported to be alternatively spliced.
However, no isoform 2 transcripts with alternative splicing
of coding exons were detected.
To find out whether alternative RAD51 splicing that pro-
duces isoforms 1 and 2 transcripts is present in mammary
gland and is not limited to lymphoblastoid cell lines, we
studied human mammary epithelial cells and four human
breast cancer cell lines: MCF-7, MDA-MB-157, ZR-75-1,
and T47D. Both isoforms 1 and 2 were detected in the
breast epithelium and cancer samples tested (data not
shown).
Discussion
In this study, we combined data from 19 studies to in-
vestigate the effect of the RAD51 135GrC SNP on breast
cancer risk among BRCA1 and BRCA2 female mutation
carriers and found evidence that this polymorphism is
associated with breast cancer risk among BRCA2 mutation
carriers ( , by trend test; , by 2-df test).Pp .007 Pp .0007
We found no evidence of a higher risk in GC heterozy-
gotes, and the sample size was sufficient to rule out any
1194 The American Journal of Human Genetics Volume 81 December 2007 www.ajhg.org
Figure 2. Relative levels of the RAD51 isoforms 1 and 2 transcripts by genotype, measured by quantitative RT-PCR in lymphoblastoid
cell lines established from individuals with different RAD51 135GrC genotypes. The relative expression level of each RAD51 isoform
across the three 135G/C variant genotypes was normalized by the geometric mean of the expression level of the reference housekeeping
genes (in experiment 1, G6PD; in experiment 2, GAPDH and ACTB) and are given in arbitrary units relative to the mean level for the
GG genotype. Two replicates were performed for each experiment. The nonparametric Kruskal-Wallis tests were performed to investigate
differences in the distributions of the isoform levels across the genotypes.
substantial risk in this group (HR 1.17 [95% CI 0.91–1.51]).
However, we found strong evidence of an increased risk
in CC homozygotes (HR 3.18 [95% CI 1.39–7.27]). The
association with breast cancer risk was weaker or nonex-
istent in BRCA1 carriers, but larger studies will be needed
to determine whether there is any association in this
group.
Since CC homozygotes are rare, previous studies would
have been too small to detect this effect. Only a study of
this size, made possible through the CIMBA collaboration,
allows such effects to be detected reliably. The association
with risk in BRCA2 carriers was essentially unaltered by
restriction to incident cases and by adjustment for pro-
phylactic oophorectomy.
There was some evidence of heterogeneity in the HRs
between the studies for BRCA2 mutation carriers. How-
ever, this may be partly because of the very small number
of rare homozygotes in each study, which results in im-
precise study-specific estimates. Studies with larger num-
bers of BRCA2 mutation carriers are required to clarify this
further.
Three previously published studies found evidence that
carriers of the 135C allele among BRCA2 mutation carriers
were at a significantly increased risk of breast cancer,11–13
with the evidence largely coming from the heterozygotes.
Although the data from one of these studies are included
in the current combined CIMBA analysis11 and although
partial overlap may exist with the other two studies, which
we cannot establish with certainty, we did not find
significant evidence of an increased risk among the
heterozygotes.
Two additional studies investigated the effect of the
RAD51 135GrC polymorphism among Polish BRCA1 mu-
tation carriers and found a significant protective effect
among carriers of the 135C allele.14,15 These data were in-
cluded in the CIMBA analysis (as a subset of the IHCC
study), but the combined analysis does not support this
finding. This discrepancy may reflect differences in the
eligibility criteria for participation in each study, differ-
ences in the study size, or differences in the statistical
methods used. In the present analysis, the IHCC study–
specific HR estimates were not significantly different from
1 for either the heterozygotes or the rare homozygotes.
Interestingly, 93% of the carriers in the IHCC group carry
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BRCA1 class 2 mutations, for which no effect was detected
in our analysis.
The effect of the RAD51 135GrC SNP in unselected
series of breast cancer cases has been investigated in a
small number of studies. Kuschel et al.40 found no signif-
icant association with breast cancer among heterozygote
carriers, whereas the OR estimate for rare homozygotes
was 2.5 (95% CI 0.6–10.9). However, preliminary analyses
of a larger sample from the same population found an OR
of 0.97 (95% CI 0.45–2.07) among the CC homozygotes
(K. Pooley, personal communication). Another popula-
tion-based study from Australia also found no evidence
of association with breast cancer risk.41 These observations
raise the possibility that the association between RAD51
135GrC and breast cancer risk is specific to BRCA2
carriers.
BRCA2 mediates the homologous recombination activ-
ity of RAD51 through binding to this DNA recombinase
and is essential for the repair of DNA double-strand
breaks.6,47 The effect on breast cancer risk observed in our
study suggests an interaction between the functional out-
comes of the RAD51 135C allele and BRCA2-inactivating
mutations. Because of the strong linkage disequilibrium
in this region, genetic studies cannot distinguish whether
the association is being driven by RAD51 135GrC itself
or by other polymorphisms in the region (including
CASC5), but RAD51 135GrC is the most plausible caus-
ative variant. Prior characterization of RAD51 suggested
that it contains a 747-nt basic promoter region that in-
cludes the 135GrC polymorphic site.48 Furthermore, ex-
pression constructs containing the 135C allele had higher
activity than that of the wild type.
Our study suggests an effect of the RAD51 135GrC var-
iant on the RAD51 alternative splicing within the 5′ UTR.
The level of the RAD51 alternative isoform 2 transcript is
significantly decreased in the lymphoblastoid cell lines of
135CC homozygotes, compared with other genotypes. In-
terestingly, the part of the 5′ UTR sequence that is lacking
in isoform 2 has a particularly high GC content (77%) and
is predicted to create highly stable stem-loop secondary
structures (RNA and DNA Folding Applications).49 Such
structures are known to negatively regulate the translation
potential, by inhibiting binding or scanning of the trans-
lation machinery.50,51 Therefore, isoform 2 would be ex-
pected to have high translation efficiency. These findings
suggest that the RAD51 135C allele may cause an overall
lower abundance of RAD51 protein, thereby providing an
insight into the molecular mechanism through which this
RAD51 variant may affect cancer risk. Further studies will
be needed to characterize the consequences of this SNP
at the protein level, particularly in breast tissue.
The identification of RAD51 as a genetic modifier may
have implications for the clinical management of BRCA2
mutation carriers. On the basis of the estimated HR in CC
homozygotes, the estimated absolute risk of breast cancer
in BRCA2 carriers by age 70 years in the most recent birth
cohort would be 90% in CC homozygotes, compared with
51% in GG homozygotes. This difference may be suffi-
ciently large to alter management for those rare patients
who are RAD51 CC homozygotes.
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Appendix A
Retrospective Likelihood Approach and Score Test
Analytical Framework
We assume that the study includes n carriers who receive
a diagnosis of breast cancer at ages andt ,t ,…,t m n1 2 n
unaffected carriers censored at ages and that wet ,…,tn1 m
observe genotype vectors (or, in general, otherz ,z ,…,z1 2 m
covariates) for these individuals. We assume that the
breast cancer incidence rate for individual i depends on
the underlying genotype through a Cox proportional haz-
ards model: . Our aim is to estimatetl (t)p l (t) exp(b z )i 0 i
and perform significance tests on the log-risk ratios b. Note
that the baseline incidence rate is not known but canl (t)0
be inferred from the overall incidence rates obtained,m(t)
for example, from external sources.
Retrospective Likelihood
The conditional likelihood of the genotypes (assumed
to be random effects) given the disease phenotypes can
be written as
m t tp exp[L (t ) exp(b z ) b z O ]g 0 i g g ii i iLp , t t
ip1p exp[L (t ) exp(b z ) b z O ]k 0 i k k i
k
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where the summation in the denominator is over all ge-
notypes, is the frequency of genotype k, and is 0p Ok i
(zero) if individual i is unaffected and 1 if affected. L (t)0
is the baseline cumulative incidence rate and(p  l (u))0
is unknown but can be obtained by constraining the over-
all incidence to agree with the assumed incidence rates
for BRCA1 and BRCA2 mutation carriers as described else-
where.29 This is a true likelihood and can be maximized
jointly over p and by use of the software MENDEL.30b
Stratified data can be dealt with by considering the strat-
ified conditional likelihood
S mj t tp exp[L (t ) exp(b z ) b z O ]g j0 ji g g jiji ji jiLp , t t
jp1 ip1p exp[L (t ) exp(b z ) b z O ]k j0 ji k k jij j j
kj
where is the frequency of the kth genotype within stra-pkj
tum j ( ) and the subscript ji indicates the ob-jp 1,…,S
served data for individual i in the jth stratum. This like-
lihood can be maximized jointly over and the stratumb
specific genotype frequencies.
Score Test
By use of the likelihood, it is also possible to derive the
score test statistic for testing the null hypothesis :H0
. Let U represent the score vector. Following the no-bp 0
tation in the previous section, it can be shown that, under
the null hypothesis, the kth element of U has the form
m
¯U p (z  z ) [O L (t )] ,k ki k i 0 i
ip1
where is value of the covariate for the ith individualzki
and is the mean of the kth covariate over all individuals.z¯k
Under the null hypothesis, the statistic has a x2t 1U V U
distribution with df, where V is the information ma-n 1
trix under the null hypothesis and n is the dimension of
the covariate vector z. A stratified version of the test can
also be derived. This test is fully efficient when the effect
size is small and agrees with the true incidence ratesl (t)0
but is valid even if these assumptions are not met. The
score test is similar in concept to the log-rank test used in
standard survival analysis.32 The difference is that, in the
log-rank test, the expected number of events is computed
using observed data, whereas, in this test, the expected
number is based on the assumed carrier incidence rates.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Breast Cancer Information Core, http://research.nhgri.nih.gov/
projects/bic/
ESE Finder, http://rulai.cshl.edu/tools/ESE/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for RAD51
transcripts [accession numbers NM_002875 and AK131299])
International HapMap Project, http://www.hapmap.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for BRCA1, BRCA2, G6PD, GAPDH,
ACTB, and CASC5)
RNA and DNA Folding Applications, http://www.bioinfo.rpi.edu/
applications/mfold/
SpliceSiteFinder, http://violin.genet.sickkids.on.ca/˜ali/
splicesitefinder.html
Splice Site Prediction, http://www.fruitfly.org/seq_tools/splice
.html
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